These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28314411)

  • 21. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
    Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
    J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
    Li X
    Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
    Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications.
    Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Kleinschek MA; Li C; Liu D; Maclean JK; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Yang R
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5384-8. PubMed ID: 26403930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
    Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
    J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of a Novel and Selective IRAK4 Inhibitor Using Topological Water Network Analysis and Molecular Modeling Approaches.
    Lee MH; Balupuri A; Jung YR; Choi S; Lee A; Cho YS; Kang NS
    Molecules; 2018 Nov; 23(12):. PubMed ID: 30501110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
    Lavazais S; Jargosch M; Dupont S; Labéguère F; Menet C; Jagerschmidt C; Ohm F; Kupcsik L; Parent I; Cottereaux C; Marsais F; Oste L; Van de Water A; Christophe T; De Vos S; Fallon P; Lauffer F; Clément-Lacroix P; Eyerich K; Brys R
    Sci Transl Med; 2023 Feb; 15(683):eabj3289. PubMed ID: 36791209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury.
    Zou Y; Wang X; Chen P; Zheng Z; Li X; Chen Z; Guo M; Zhou Y; Sun C; Wang R; Zhu W; Zheng P; Cho WJ; Cho YC; Liang G; Tang Q
    J Med Chem; 2024 Jul; 67(13):10687-10709. PubMed ID: 38913701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
    Hao Y; Ma J; Wang J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
    Eur J Med Chem; 2023 Oct; 258():115616. PubMed ID: 37413880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1 Receptor-Associated Kinase 1/4 as a Novel Target for Inhibiting Neointimal Formation After Carotid Balloon Injury.
    Bai S; Li D; Zhou Z; Cao J; Xu T; Zhang X; Wang Y; Guo J; Zhang Y
    J Atheroscler Thromb; 2015; 22(12):1317-37. PubMed ID: 26310493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IRAK4 as a molecular target in the amelioration of innate immunity-related endotoxic shock and acute liver injury by chlorogenic acid.
    Park SH; Baek SI; Yun J; Lee S; Yoon DY; Jung JK; Jung SH; Hwang BY; Hong JT; Han SB; Kim Y
    J Immunol; 2015 Feb; 194(3):1122-30. PubMed ID: 25548221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IRAK-4 inhibitors. Part 1: a series of amides.
    Buckley GM; Gowers L; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V; Fraser JL
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3211-4. PubMed ID: 18474425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the interleukin 1 receptor-associated kinase 4 (IRAK4)-encoding gene in salmonid fish: the functional copy is rearranged in Oncorhynchus mykiss and that factor can impair TLR signaling in mammalian cells.
    Brietzke A; Goldammer T; Rebl H; Korytář T; Köllner B; Yang W; Rebl A; Seyfert HM
    Fish Shellfish Immunol; 2014 Jan; 36(1):206-14. PubMed ID: 24239597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.
    Chen Y; Tso K; Heckrodt TJ; Li H; Yen R; Lin N; Singh R; Taylor V; Masuda ES; Park G; Payan DG
    Bioorg Med Chem Lett; 2022 Oct; 73():128900. PubMed ID: 35863718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
    Degorce SL; Anjum R; Dillman KS; Drew L; Groombridge SD; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Scott JS; Stokes S; Xue Y
    Bioorg Med Chem; 2018 Feb; 26(4):913-924. PubMed ID: 29398441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IRAK4 turns IL-10+ phospho-FOXO+ monocytes into pro-inflammatory cells by suppression of protein kinase B.
    Over B; Ziegler S; Foermer S; Weber AN; Bode KA; Heeg K; Bekeredjian-Ding I
    Eur J Immunol; 2013 Jun; 43(6):1630-42. PubMed ID: 23519847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural dynamic analysis of apo and ATP-bound IRAK4 kinase.
    Gosu V; Choi S
    Sci Rep; 2014 Jul; 4():5748. PubMed ID: 25034608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model.
    Hao Y; Wang J; Ma J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
    Bioorg Chem; 2023 Aug; 137():106584. PubMed ID: 37163814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cloning and functional characterization of IRAK4 in large yellow croaker (Larimichthys crocea) that associates with MyD88 but impairs NF-κB activation.
    Zou PF; Huang XN; Yao CL; Sun QX; Li Y; Zhu Q; Yu ZX; Fan ZJ
    Fish Shellfish Immunol; 2017 Apr; 63():452-464. PubMed ID: 27989863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insights into molecular profiles and genomic evolution of an IRAK4 homolog from rock bream (Oplegnathus fasciatus): immunogen- and pathogen-induced transcriptional expression.
    Umasuthan N; Bathige SD; Whang I; Lim BS; Choi CY; Lee J
    Fish Shellfish Immunol; 2015 Apr; 43(2):436-48. PubMed ID: 25555811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.